EGFR and malignant colon neoplasm: More importantly, we found that left-side CRC and right-side colon cancer have distinct immune landscapes, and that this immune landscape might, to some extent, explain the primary CRC location-specific differences in prognoses and responses to anti-VEGF and anti-EGFR agents.